If you are exploring options for joint wear without wanting surgery, one question arises naturally: can anything useful be done in a single appointment? ChondroFiller is a non-surgical collagen scaffold delivered as an outpatient injection. This article sets out what to expect, what the evidence suggests, and how the injection relates to other cartilage-restoration approaches — with realistic expectations throughout.

What ChondroFiller Is and How It Works

ChondroFiller is a CE-marked Class III medical device made from type I collagen. When injected into a joint, the gel settles within the worn area, providing a structural matrix that recruits the body's own progenitor cells to migrate in and begin laying down new cartilage tissue. It is acellular — there are no donor or harvested cells in the product — which means no additional surgery is needed to collect cells before or during treatment. The gel self-sets over a few minutes and adheres to the surrounding tissue without sutures.

The device is designed to act as a biological scaffold rather than a cushioning filler alone. Over months to years, the original collagen matrix is gradually resorbed as the body's own cells remodel the area. It should be understood as a regenerative support measure, not a cure or reversal of arthritis.

The Single-Session Treatment: What to Expect

ChondroFiller is delivered as a minimally invasive, ultrasound-guided injection in an outpatient setting. Imaging is used throughout to direct a fine needle precisely into the joint. There is no theatre, no incision, and no general anaesthetic. Because the procedure is non-surgical, recovery is typically straightforward — most people resume normal daily activities promptly, easing back into higher-impact activity over the following weeks as advised by their clinician. There is no requirement for the protected weight-bearing that follows joint surgery.

What the Evidence Suggests

Clinical evidence for ChondroFiller is still developing but shows encouraging early results. In published series, patient-reported outcome scores for the knee have improved by approximately 30 points on the International Knee Documentation Committee (IKDC) scale over 12 to 36 months. In the hip, modified Harris Hip Score (mHHS) improvements of more than 30 points have been reported. Imaging using MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scoring has demonstrated scores of around 80 and above in cartilage repair tissue quality at follow-up, indicating good defect fill and tissue integration.

For smaller joints, a 2023 study examined the use of an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis and reported meaningful improvements in pain and grip strength following a single injection (Corain et al., 2023, Cartilage). These findings reflect early and intermediate data; individual responses vary, and benefits cannot be guaranteed for any patient.

Who May Be Suitable

The injection may suit adults with localised cartilage wear or osteoarthritis who want a non-surgical option and are not at the stage requiring joint replacement. It is generally considered for ICRS Grade I to IV cartilage defects up to 6 cm2 across a range of joints, including the knee, hip, shoulder, ankle, and smaller joints. Very advanced arthritis, active joint infection, or inflammatory joint disease affecting the target joint may make the injection less appropriate. Individual assessment by a clinician experienced in joint preservation is essential before proceeding.

ChondroFiller Injection and the Liquid Cartilage Surgical Protocol

The ChondroFiller injection is sometimes confused with the Liquid Cartilage protocol — they are distinct. ChondroFiller is the CE-marked collagen scaffold itself; the injection is one non-surgical delivery method for it. The Liquid Cartilage protocol is a separate, keyhole (arthroscopic) surgical procedure developed at the London Cartilage Clinic, in which the ChondroFiller scaffold is placed under direct vision during surgery and combined with biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own mesenchymal stem cells from bone-marrow concentrate or micro-fragmented fat. The surgical approach is suited to larger or more complex defects where arthroscopic placement and biologic augmentation may offer greater precision than an injection alone. It requires theatre, anaesthetic, and a structured rehabilitation programme.

For straightforward, accessible defects, the single-session injection pathway is often the appropriate starting point. For patients with larger lesions or those who do not respond adequately to injection, the surgical protocol may be considered at a subsequent consultation.

Practical Considerations and Safety

ChondroFiller has a well-documented safety record in published clinical data. Across a large number of units used since 2013, no serious device-related incidents have been reported, and complication rates in clinical studies are very low. As with any joint injection, minor risks such as temporary discomfort, swelling, or a low risk of infection exist and are discussed at the time of assessment. The treating clinician will explain what to monitor after the injection and when to seek follow-up review.

Conclusion

A single-session ChondroFiller injection offers a non-surgical option that may support a worn joint and ease symptoms, with a straightforward recovery. Whether it is suitable depends on the nature and extent of the cartilage damage, the joint involved, and each person's overall health and goals. At the London Cartilage Clinic, clinicians with expertise in joint preservation can assess whether this approach, the Liquid Cartilage surgical protocol, or another pathway is the most appropriate first step for your situation.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.